445 related articles for article (PubMed ID: 20176003)
21. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
22. New and reliable MRI diagnosis for progressive supranuclear palsy.
Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S
Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570
[TBL] [Abstract][Full Text] [Related]
23. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
24. Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease.
Rascol O; Sabatini U; Fabre N; Senard JM; Simonetta-Moreau M; Montastruc JL; Clanet M; Rascol A
Mov Disord; 1995 Mar; 10(2):163-70. PubMed ID: 7753058
[TBL] [Abstract][Full Text] [Related]
25. Coexistence of PSP and MSA: a case report and review of the literature.
Uchikado H; DelleDonne A; Uitti R; Dickson DW
Acta Neuropathol; 2006 Feb; 111(2):186-92. PubMed ID: 16456665
[TBL] [Abstract][Full Text] [Related]
26. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
27. Functional mapping in PD and PSP for sustained phonation and phoneme tasks.
Sachin S; Senthil Kumaran S; Singh S; Goyal V; Shukla G; Mahajan H; Behari M
J Neurol Sci; 2008 Oct; 273(1-2):51-6. PubMed ID: 18675995
[TBL] [Abstract][Full Text] [Related]
28. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
Jellinger KA
Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
[TBL] [Abstract][Full Text] [Related]
29. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
30. Dual immunofluorescence study of citrullinated proteins in Parkinson diseased substantia nigra.
Nicholas AP
Neurosci Lett; 2011 May; 495(1):26-9. PubMed ID: 21414385
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.
Schulz JB; Skalej M; Wedekind D; Luft AR; Abele M; Voigt K; Dichgans J; Klockgether T
Ann Neurol; 1999 Jan; 45(1):65-74. PubMed ID: 9894879
[TBL] [Abstract][Full Text] [Related]
32. Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
Taylor JM; Song YJ; Huang Y; Farrer MJ; Delatycki MB; Halliday GM; Lockhart PJ
Neurobiol Dis; 2007 Aug; 27(2):238-47. PubMed ID: 17590346
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss.
Iczkiewicz J; Rose S; Jenner P
Exp Neurol; 2007 Sep; 207(1):95-106. PubMed ID: 17643430
[TBL] [Abstract][Full Text] [Related]
34. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
35. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Tong J; Fitzmaurice PS; Ang LC; Furukawa Y; Guttman M; Kish SJ
Ann Neurol; 2004 Jan; 55(1):125-9. PubMed ID: 14705122
[TBL] [Abstract][Full Text] [Related]
36. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
Kashihara K; Shinya T; Higaki F
Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
[TBL] [Abstract][Full Text] [Related]
37. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
38. Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses.
Zouambia M; Fischer DF; Hobo B; De Vos RA; Hol EM; Varndell IM; Sheppard PW; Van Leeuwen FW
Proteomics; 2008 Mar; 8(6):1221-36. PubMed ID: 18283660
[TBL] [Abstract][Full Text] [Related]
39. An altered histaminergic innervation of the substantia nigra in Parkinson's disease.
Anichtchik OV; Rinne JO; Kalimo H; Panula P
Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440
[TBL] [Abstract][Full Text] [Related]
40. A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.
De Pablo-Fernández E; Courtney R; Warner TT; Holton JL
JAMA Neurol; 2018 Aug; 75(8):1008-1012. PubMed ID: 29710120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
